GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Rangering i aksjer
#3670
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Aksjekurs
$27.08
Markedsverdi
$4.59B
Endring (1 dag)
-1.68%
Endring (1 år)
-13.61%
Land
IN
Handel GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Kategori
Healthcare
Antall utestående aksjer for GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Antall utestående aksjer per June 2026: 169.41M
Ifølge GlaxoSmithKline Pharmaceuticals Limited sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 169.41M. Ved slutten av March 2024 hadde selskapet 169.41M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for GlaxoSmithKline Pharmaceuticals Limited (GLAXO) fra 2004 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 169.41M | 0.00% |
| 2025 | 169.41M | 0.00% |
| 2024 | 169.41M | -0.50% |
| 2023 | 170.26M | -4.88% |
| 2022 | 178.98M | 5.65% |
| 2021 | 169.41M | 0.00% |
| 2020 | 169.41M | 0.00% |
| 2019 | 169.41M | 0.00% |
| 2018 | 169.41M | 0.00% |
| 2017 | 169.41M | 0.00% |
| 2016 | 169.41M | 0.00% |
| 2015 | 169.41M | 0.00% |
| 2013 | 169.41M | 0.00% |
| 2012 | 169.41M | 0.00% |
| 2011 | 169.41M | 0.00% |
| 2010 | 169.41M | 0.00% |
| 2009 | 169.41M | 0.00% |
| 2008 | 169.41M | 0.00% |
| 2007 | 169.41M | 0.00% |
| 2006 | 169.41M | -1.29% |
| 2005 | 171.62M | -1.73% |
| 2004 | 174.65M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 892.40M | 426.78% |
US
|
|
| 2.45B | 1,344.78% |
US
|
|
| 1.77B | 945.41% |
US
|
|
| 0.00 | -100.00% |
US
|
|
| 796.00M | 369.88% |
CH
|
